Novo Nordisk Partners With Hims on Wegovy, Ozempic Sales

Novo Nordisk and telehealth company Hims & Hers Health announced a partnership on Monday that resolves an ongoing patent infringement lawsuit and allows the Danish drugmaker to sell its branded weight loss medications, including Wegovy and Ozempic, through the Hims platform starting later this month.

The agreement comes just weeks after Novo Nordisk filed suit against Hims in early February, accusing the company of infringing on patents related to semaglutide, the active ingredient in its blockbuster GLP-1 drugs used for obesity and diabetes treatment. Hims had planned to launch a lower-cost, compounded version of the oral formulation of Wegovy, priced at around $49 per month, but abandoned those plans two days after the lawsuit. That decision followed a warning from the U.S. Food and Drug Administration, which threatened to restrict access to ingredients for such compounded drugs.

Under the new deal, Hims will offer both oral and injectable versions of Wegovy and Ozempic directly to its customers, who often pay out of pocket for these high-demand treatments. In exchange, Hims has agreed to cease advertising or marketing compounded GLP-1 drugs on its platform. Novo Nordisk...